(firstQuint)Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma.

 Patients with follicular lymphoma who require therapy and have been previously untreated are eligible for this non-randomized, phase II study evaluating up front therapy with CHOP-R x 3 cycles followed by zevalin and 4 additional weeks of rituxan.

The complete response will be determined by combining IWC criteria and PET scanning.

Secondary objectives include PET-CT conversion rate, frequency and severity of adverse events, duration of complete remission and time to next lymphoma therapy.

.

 Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma@highlight

The purpose of this study is to determine the complete response rate when CHOP-R chemotherapy in followed by Zevalin in previous untreated patients with follicular lymphoma